At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 9 enrolled
Drug / intervention
Vismodegibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pharmacodynamic Study of Vismodegib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC) With Accessible Metastatic Lesions for Tumor Biopsy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Apr 16, 2014·Updated Jul 20, 2018
In Brief
A Early Phase 1 clinical trial evaluating Vismodegib for Prostate Cancer. Completed, enrolled 9 participants across 1 site.
Detailed Summary
This is a single-arm pharmacodynamic study with mandatory metastatic tumor biopsies in men with castration-resistant prostate cancer. The trial will evaluate the effect of vismodegib on tumor tissue in men with metastatic CRPC by obtaining tumor biopsies at baseline and after 4 weeks of treatment with vismodegib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
Early Ph 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
First PostedApr 2014
Primary CompletionApr 2016
TodayJul 2026
First PostedApr 16, 2014
Enrollment StartApr 1, 2014
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.2 years ago
Interventions
Vismodegibdrug